NW 41231 A
Alternative Names: NW-41231-ALatest Information Update: 31 Mar 2025
At a glance
- Originator Newave Pharmaceuticals
- Developer Guangzhou Lupeng Pharmaceutical; Newave Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 31 Mar 2025 Early research in Cancer in China (unspecified route) before March 2025 (Guangzhou Lupeng Pharmaceutical pipeline, March 2025)
- 31 Mar 2025 Early research in Cancer in USA (unspecified route) before March 2025 (Guangzhou Lupeng Pharmaceutical pipeline, March 2025)